NCT05173714RecruitingPhase 2
Sit Less, Interact and Move More (SLIMM) 2 Study
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- First submitted
- 4 Nov 2021
- Start date
- 1 Dec 2021
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Srinvasan Beddhu
- Diseases
- Chronic kidney disease, Obesity
- NCT number
- NCT05173714
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 156
- From 1 Dec 2021 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous bariatric surgery
- Anticipated start of dialysis or kidney transplantation within 6 months
- Enrolled in interventional trials using drugs or devices
- Use of any GLP-1 receptor agonist within 30 days prior to screening
Other illness
- Type 1 Diabetes
- History of gastroparesis or paralytic ileus
- Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
- Medical condition likely to limit survival to less than 1 year
- Known or suspected hypersensitivity to tegaderm
- Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
- Presence of metastatic cancer
Other
- At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
- Any factors judged by the investigator or study team to likely limit adherence to interventions
- Vulnerable populations- pregnant or incarcerated
- Not able to undergo informed consent
- Recent hospitalizations or major interventional procedures done within the past 60 days
- Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
- Current use of mobility aid(s)
- Living in the same household of a participant already enrolled in the study
Who the study is looking for
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
- Able to perform resistance training
- Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Recruiting |
| Stanford University Coordinator of this site? Confirm its status | Stanford | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.